Lupin Limited has informed the Exchange regarding a press release dated Jun 08, 2026, titled "Lupin Collaborates with ERN for Luforbec® (beclometasone/formoterol) pMDI Launch in Spain".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin has announced a collaboration with ERN, a Spanish pharmaceutical company, to launch Luforbec® — a pressurized metered dose inhaler combining beclometasone and formoterol, used for treating asthma and COPD — in the Spanish market. The partnership leverages ERN's local distribution and sales network to commercialize the product in Spain. Luforbec® is an established inhaled therapy product in Lupin's respiratory portfolio. This move represents Lupin's continued push to expand its respiratory franchise across European markets through regional partnerships rather than direct entry.
Positive for shareholders — expands Lupin's international respiratory footprint and opens access to the Spanish inhaler market via a low-risk partnership model, though specific financial terms and revenue contribution were not disclosed.